Vanguard Group Inc. Has $1.28 Million Stock Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX)

Vanguard Group Inc. raised its holdings in shares of GeoVax Labs, Inc. (NASDAQ:GOVX) by 407.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 256,621 shares of the company’s stock after buying an additional 206,070 shares during the period. Vanguard Group Inc.’s holdings in GeoVax Labs were worth $1,283,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Citadel Advisors LLC acquired a new stake in shares of GeoVax Labs during the first quarter worth $330,000. Virtu Financial LLC lifted its holdings in shares of GeoVax Labs by 367.2% during the first quarter. Virtu Financial LLC now owns 60,493 shares of the company’s stock worth $265,000 after buying an additional 47,546 shares in the last quarter. Geode Capital Management LLC acquired a new stake in shares of GeoVax Labs during the first quarter worth $164,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of GeoVax Labs during the first quarter worth $46,000. 6.29% of the stock is owned by institutional investors.

Shares of NASDAQ GOVX opened at $4.69 on Friday. GeoVax Labs, Inc. has a 52 week low of $2.62 and a 52 week high of $8.71. The stock’s fifty day moving average is $4.08 and its 200 day moving average is $4.64.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, November 11th. The company reported ($0.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.06. GeoVax Labs had a negative return on equity of 36.51% and a negative net margin of 1,305.93%.

Separately, Maxim Group initiated coverage on GeoVax Labs in a report on Friday, November 12th. They set a “buy” rating and a $10.00 target price for the company.

GeoVax Labs Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever; Zika virus and malari; human immunodeficiency virus (HIV); as well as immunotherapies for solid tumor cancers.

Featured Article: What is a conference call?

Want to see what other hedge funds are holding GOVX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeoVax Labs, Inc. (NASDAQ:GOVX).

Institutional Ownership by Quarter for GeoVax Labs (NASDAQ:GOVX)